Please use this identifier to cite or link to this item:
|Title:||Orally active peptidic bradykinin B1 receptor antagonists engineered from a cyclotide scaffold for inflammatory pain treatment||Authors:||Wong, Clarence T. T.
Rowlands, Dewi K.
Lo, Theodore W. C.
Nguyen, Giang K. T.
Tam, James P.
|Keywords:||DRNTU::Science::Biological sciences||Issue Date:||2012||Source:||Wong, C. T. T., Rowlands, D. K., Wong, C.-H., Lo, T. W. C., Nguyen, G. K. T., Li, H.-Y., et al. (2012). Orally Active Peptidic Bradykinin B1 Receptor Antagonists Engineered from a Cyclotide Scaffold for Inflammatory Pain Treatment. Angewandte Chemie International Edition, 51(23), 5620-5624.||Series/Report no.:||Angewandte chemie international edition||Abstract:||Edible: By grafting natural peptide antagonists onto the cyclotide kalata B1, orally active peptides were engineered, which are potentially useful therapeutics for the treatment of inflammatory pain. For example, the entire loop 6 of kalata B1 was replaced with the peptidic bradykinin B1 receptor antagonist DALK (red in scheme) to obtain the cyclic bradykinin antagonist ckb-kal.||URI:||https://hdl.handle.net/10356/98385
|ISSN:||1433-7851||DOI:||10.1002/anie.201200984||Rights:||© 2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.||Fulltext Permission:||none||Fulltext Availability:||No Fulltext|
|Appears in Collections:||SBS Journal Articles|
Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.